128 related articles for article (PubMed ID: 21171829)
1. The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland.
Herse F; Reissell E
Scand J Infect Dis; 2011 Mar; 43(3):209-15. PubMed ID: 21171829
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
3. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. Health and economic burden of HPV-related diseases in Singapore.
Low JJ; Ko Y; Ilancheran A; Zhang XH; Singhal PK; Tay SK
Asian Pac J Cancer Prev; 2012; 13(1):305-8. PubMed ID: 22502690
[TBL] [Abstract][Full Text] [Related]
6. Resource Use and Cost of Treating Human Papillomavirus-Related Lesions in Japanese Women.
Mizukami A; Kaise T; Van Kriekinge G
Value Health Reg Issues; 2018 May; 15():56-62. PubMed ID: 29474179
[TBL] [Abstract][Full Text] [Related]
7. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
9. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
11. Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study.
Mennini FS; Fabiano G; Marcellusi A; Sciattella P; Saia M; Cocchio S; Baldo V
Clin Drug Investig; 2018 Feb; 38(2):173-180. PubMed ID: 29081028
[TBL] [Abstract][Full Text] [Related]
12. [Detection of human papillomavirus DNA by molecular hybridization in tube: interest in cervical neoplasia].
Bellagra N; Hober D; Idrissi Y; Dewilde A; Laussel Reira AC; Boman F; Leroy JL; Wattré P
Ann Biol Clin (Paris); 1999; 57(5):589-93. PubMed ID: 10518061
[TBL] [Abstract][Full Text] [Related]
13. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.
Brisson M; Van de Velde N; De Wals P; Boily MC
Vaccine; 2007 Jul; 25(29):5399-408. PubMed ID: 17561316
[TBL] [Abstract][Full Text] [Related]
14. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of human papillomavirus-related diseases in Italy.
Baio G; Capone A; Marcellusi A; Mennini FS; Favato G
PLoS One; 2012; 7(11):e49699. PubMed ID: 23185412
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus detection using in situ hybridization and correlations with histological and cytological findings.
Laabidi B; Ben Rejeb S; Bani A; Mansouri N; Lamine O; Bouzaini A; Msakni I
Med Mal Infect; 2016 Oct; 46(7):380-384. PubMed ID: 27596714
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and associated costs for genital warts in Italy.
Merito M; Largeron N; Cohet C; Timelli L; Boselli F; Matteelli A; Naldi L; Vittori G
Curr Med Res Opin; 2008 Nov; 24(11):3175-83. PubMed ID: 18851777
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of genital human papillomavirus infection in a female adolescent population.
Jamison JH; Kaplan DW; Hamman R; Eagar R; Beach R; Douglas JM
Sex Transm Dis; 1995; 22(4):236-43. PubMed ID: 7482107
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic implications of adding HPV tests to the routine cytology follow-up and management of patients with histologically defined cervical intraepithelial neoplasia grade 1.
Gamzu R; Almog B; Levin I; Fainaru O; Niv J; Lessing JB; Bar-Am A
Gynecol Oncol; 2002 Aug; 86(2):129-33. PubMed ID: 12144817
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre.
Hampl M; Huppertz E; Schulz-Holstege O; Kok P; Schmitter S
BMC Infect Dis; 2011 Mar; 11():73. PubMed ID: 21426562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
